Arrowhead Pharmaceuticals to Present at Upcoming May Conferences

Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions – Nashville, May 5-7, 2016

May 6, 11:00 a.m. CDT – Stacey Melquist, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, “Lipoprotein(a) targeting with RNAi delivery platforms in transgenic mice and cynomolgus monkeys” (Presentation Number 428)

IBC’s 18th Annual TIDES: Oligonucleotide and Peptide Therapeutics – Long Beach, California, May 9-12, 2016

May 9, 1:30 p.m. PDT – David Rozema, Ph.D., Arrowhead vice president of chemistry will deliver an oral presentation titled, “Protease-sensitive endosomal escape for delivery of siRNA in vivo

May 9, 1:30 p.m. PDT – Qingguo Tian, Ph.D., Arrowhead bioanalytical project manager will deliver an oral presentation titled, “Sensitive and specific quantification of oligonucleotides in biological matrices using hybridization based LC-fluorescence assays

5th Asian Conference on Hepatitis and AIDS (ACHA) – Nanjing, China, May 28-29, 2016

May 29, 4:50 p.m. CST (China Standard Tim) – Bruce Given, M.D., Arrowhead chief operating officer will deliver an oral presentation titled, “RNAi therapeutics for chronic HBV – Animal models

Copies of presentation materials can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each presentation is delivered.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

Contacts

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

ir@arrowheadpharma.com
or
Investor Relations:
The Trout Group
Chad Rubin, 646-378-2947

ir@arrowheadpharma.com
or
Media:
Russo Partners
Matt Middleman, M.D.
212-845-4272

matt.middleman@russopartnersllc.com